Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Net Income Loss of -$124.02 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +4.6% in Net Income Loss from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$2.09 million | Q3 2013: -$3.09 million | Q1 2014: -$5.16 million | Q2 2014: -$6.04 million | Q3 2014: -$7.42 million | Q4 2014: -$8.99 million | Q1 2015: -$9.68 million | Q2 2015: -$11.76 million | Q3 2015: -$13.25 million | Q4 2015: -$13.36 million | Q1 2016: -$13.98 million | Q2 2016: -$9.81 million | Q3 2016: -$7.58 million | Q1 2017: -$5.06 million | Q2 2017: -$4.78 million | Q3 2017: -$5.79 million | Q1 2018: -$6.94 million | Q2 2018: -$6.09 million | Q3 2018: -$5.48 million | Q1 2019: -$6.23 million | Q2 2019: -$5.84 million | Q3 2019: -$7.84 million | Q1 2020: -$7.27 million | Q2 2020: -$14.18 million | Q3 2020: -$11.99 million | Q1 2021: -$20.65 million | Q2 2021: -$23.55 million | Q3 2021: -$18.53 million | Q1 2022: -$26.42 million | Q2 2022: -$23.14 million | Q3 2022: -$28.98 million | Q1 2023: -$33.01 million | Q2 2023: -$28.36 million | Q3 2023: -$27.98 million | Q1 2024: -$14.94 million | Q2 2024: -$78.78 million | Q3 2024: -$14.21 million | Q1 2025: -$16.83 million | Q2 2025: -$28.27 million | Q3 2025: -$32.01 million.
- Over the full 18 years of available data (2008 to 2025), Tonix Pharmaceuticals Holding Corp.'s Net Income Loss has declined by 61,296.5%.
- Historical annual values: Fiscal year 2025: -$124.02 million | Fiscal year 2024: -$130.04 million | Fiscal year 2023: -$116.66 million | Fiscal year 2022: -$110.22 million | Fiscal year 2021: -$92.29 million | Fiscal year 2020: -$50.46 million | Fiscal year 2019: -$28.62 million | Fiscal year 2018: -$26.09 million | Fiscal year 2017: -$21.12 million | Fiscal year 2016: -$38.84 million | Fiscal year 2015: -$48.05 million | Fiscal year 2014: -$27.62 million | Fiscal year 2013: -$10.88 million | Fiscal year 2012: -$9.45 million | Fiscal year 2011: -$3.47 million | Fiscal year 2010: -$1.96 million | Fiscal year 2009: -$221.0 thousand | Fiscal year 2008: -$202.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: